Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Appili Therapeutics Inc APLIF


Primary Symbol: T.APLI

Healthcare
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical... see more

Recent & Breaking News (TSX:APLI)

Appili Therapeutics Enters Commercial Agreement With Saptalis Pharmaceuticals for Anticipated Launch of ATI-1501 Antibiotic Candidate in the U.S.

Business Wire December 3, 2019

Appili Therapeutics Names Dr. Armand Balboni as Chief Executive Officer

Business Wire December 2, 2019

Appili Therapeutics Reports Financial Results for Second Quarter of Fiscal Year 2020

Business Wire November 27, 2019

Appili Therapeutics Acquires Clinical Stage Antifungal Program From FUJIFILM Toyama Chemical

Business Wire November 21, 2019

Researchers Present New Positive Interim Data on Appili Therapeutics' ATI-1701 Biodefense Program at 2019 Chemical and Biological Defense Science & Technology Conference

Business Wire November 18, 2019

Appili Therapeutics Announces Voting Results of Annual and Special Meeting of Shareholders

Business Wire September 26, 2019

Appili Therapeutics Retains BND Projects for Strategic Investor Relations Services

Business Wire September 16, 2019

Appili Therapeutics Reports Financial Results for First Quarter of Fiscal Year 2020

Business Wire August 21, 2019

Researchers to Present New Data on Appili Therapeutics Infectious Disease Programs at the 2019 Military Health System Research Symposium

Business Wire August 20, 2019

Appili Therapeutics Announces FY 2019 Financial Results

Business Wire July 3, 2019

Appili Therapeutics Inc. Opens the Market

Canada NewsWire July 3, 2019

Appili Therapeutics Signs $3M USD Grant Contract with the United States Department of Defense to Develop Antibiotics that Target Superbugs

Business Wire July 2, 2019